Lupin zooms on getting EIR from USFDA for Ankleshwar manufacturing facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 699.20, up by 19.60 points or 2.88% from its previous closing of Rs. 679.60 on the BSE.
The scrip opened at Rs. 680.00 and has touched a high and low of Rs. 706.65 and Rs. 678.75 respectively. So far 41359 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 979.25 on 13-Oct-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.
Last one week high and low of the scrip stood at Rs. 706.65 and Rs. 637.60 respectively. The current market cap of the company is Rs. 30899.68 crore.
The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 41.45% and 11.45% respectively.
Lupin has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility, located in Gujarat, India. The inspection of the facility was conducted from August 16-19, 2022.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
